Aspirin can cut cancer patients' risk of death by 20 percent

Aspirin (acetylsalicylic acid), is the world's oldest, the most widely used one of the three classic drugs. Since it came into the market in 1898, aspirin has been in clinical use for more than 100 years and has become the most widely used antipyretic, analgesic and anti-inflammatory drug in the world.

In 1897, Germany's Bayer synthesized the main substance of Aspirin for the first time, which promoted the marketing process of the drug. Two years later, Bayer sold the drug worldwide under the brand name Aspirin.

In 1988, Australian scholars first proposed that aspirin could prevent cancer. As an antipyretic and analgesic drug, aspirin was officially involved in the "anti-cancer tide". Since then, studies on the correlation between aspirin and the risk of cancer as well as its anti-cancer and anti-cancer mechanisms have emerged in an endless stream.

Recently, a team from Cardiff University published a study titled Aspirin and Cancer Survival: A systematic review and meta-analysis of 118 observational studies of Aspirin and 18 cancers, The study found that taking aspirin as part of treatment for many types of cancer could reduce the risk of death by 20 percent.

The researchers conducted a systematic review of 118 observational studies that had covered patients with 18 different types of cancer. It found that among a total of about 250,000 cancer patients who reported taking aspirin, the number of deaths from cancer was reduced by about 20 percent.

Although aspirin is a kind of "universal god of medicine", but any kind of drug can avoid side effects, therefore, considering the side effects of aspirin, the researchers in addition to the related data extracted from the published report, also wrote the above into the research of the authors of the paper mail, ask whether to have stomach bleeding or other bleeding events.

The study found that a small number of patients had bleeding, but there was no evidence that patients taking aspirin had died from bleeding too much. Therefore, the available evidence on the efficacy and safety of aspirin justifies its use as an adjuvant therapy in a wide range of cancers.

                                      Aspirin use is associated with mortality